
Mytos builds robots that grow human cells. Our machines take stem cells as input, and grow them into specific cells like neurons or heart cells. Customers use our platform to scale stem-cell derived therapies to more patients sooner. We're also used to produce cells for testing new drugs on during R&D in Drug Discovery. Mytos is backed by leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. We're hiring now - visit our website to see open positions

Mytos builds robots that grow human cells. Our machines take stem cells as input, and grow them into specific cells like neurons or heart cells. Customers use our platform to scale stem-cell derived therapies to more patients sooner. We're also used to produce cells for testing new drugs on during R&D in Drug Discovery. Mytos is backed by leading investors, including YCombinator, Buckley Ventures and IQ Capital - as well as founders and execs from companies like Kite, Sana, Dropbox, and Revolut. Our team is made up of brilliant engineers from companies like Dyson and Autodesk - working hand-in-hand with Nature-published scientists. We're hiring now - visit our website to see open positions
What they do: Build automated robots (iDEM) to grow stem-cell derived human cells and operate an automated CDMO for regenerative-medicine production
HQ: London, United Kingdom
Founders: Ali Afshar and Ignacio Willats
Funding: Company states >$24M raised; reports reference a ~$19M Series A
Employee count: 48
Scaling manufacturing of stem-cell derived therapies and producing consistent, high-throughput human cells for therapeutic and drug-discovery use cases.
Biotechnology Research
$19.0M
Reported by dealroom and company newsroom
“Includes investors such as Wing Venture Capital, IQ Capital, and Buckley Ventures; additional angels and founders/executives from technology and biotech companies are listed as backers”
| Company |
|---|
You rarely get the chance to change an entire industry. But that's the position we find ourselves in. Join us, and you’ll unleash scientists, accelerate their research, and help get cures to patients sooner.
We’ve developed machines to fully automate human cell production - the most manual process in Biotech. Cells are used to discover and develop new drugs, and now they're being used to cure diseases like Parkinson’s and age-related blindness. Mytos will impact cure development across the board.
We're live in multibillion-dollar biotechs on both coasts of the US and have raised $19 million to expand into the market faster and accelerate our development! Next year, neurons grown on our machines will be going into Parkinson patient brains.
We’ve assembled a world-class team to take on this challenge, with ex-Dyson engineers and Nature-published scientists working hand-in-hand. Mytos is backed by Y Combinator, the most successful startup program in the world, which produced companies such as Airbnb, Dropbox, and Ginkgo Bioworks.
Job Title: Junior/Mid Software Engineer
Location: London
Employment Type: Full-Time
Department: Software
Work Model: Hybrid
As a Junior/Mid level Software Engineer (depending on experience), you’ll be contributing across all areas of our full-stack product based in the Cloud and our IoT devices that interface with Mytos hardware to manufacture cells. Your work will directly impact how quickly and effectively new therapies and research tools can be developed, ultimately helping patients worldwide.
We're building a team that enjoys moving fast, strives for continuous improvement through learning from mistakes, and is passionate about work that contributes to solving real-world problems. No GMP experience? No problem! We want someone who is motivated to deliver an innovative product into a regulated space with creative, efficient solutions.
If you're excited about solving interesting problems at the intersection of software, hardware, and biology while helping us prepare for the next phase of our growth, we want to hear from you!
We currently do not sponsor visas for our junior roles.